

Florence Brunet-Possenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8186506/publications.pdf>

Version: 2024-02-01

28
papers

367
citations

759233

12
h-index

839539

18
g-index

30
all docs

30
docs citations

30
times ranked

576
citing authors

#	ARTICLE	IF	CITATIONS
1	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	3.7	31
2	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e129-e129.	0.9	30
3	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	1.4	29
4	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. <i>Oncotarget</i> , 2020, 11, 378-385.	1.8	28
5	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
6	Pemphigoid gestationis: a successful preventive treatment by rituximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e206-e207.	2.4	22
7	Reply to "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance" by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 363-364.	1.2	21
8	Detection of titanium nanoparticles in the hair shafts of a patient with frontal fibrosing alopecia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e442-e443.	2.4	21
9	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	3.7	17
10	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. <i>Rheumatology</i> , 2021, 60, 5753-5764.	1.9	17
11	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1445-1452.	0.9	17
12	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
13	Focal Rituximab-Induced Edematous Reaction at Primary Cutaneous Follicle Center Lymphoma Lesions: Case Report and Literature Review. <i>Dermatology</i> , 2011, 223, 200-202.	2.1	12
14	Quality of life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	4.1	12
15	Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e498-e501.	2.4	11
16	Kaposi's Sarcoma and Pregnancy: Case Report and Literature Review. <i>Dermatology</i> , 2013, 226, 311-314.	2.1	10
17	Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 540-543.	1.2	10
18	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Presence of anti-â€•BP 180 and anti-â€•BP 230 in the cerebrospinal fluid of patients with bullous pemphigoid and neurological disease: is there any intrathecal synthesis?. <i>British Journal of Dermatology</i> , 2019, 181, 828-829.	1.5	7
20	Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients. <i>Pathology</i> , 2022, 54, 729-737.	0.6	7
21	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1441-1451.	1.3	6
22	Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection. <i>British Journal of Dermatology</i> , 2018, 179, 1179-1180.	1.5	5
23	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	3.7	3
24	Use of Combination Systemic-Intratumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas. <i>JAMA Dermatology</i> , 2019, 155, 123.	4.1	2
25	Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy. <i>JAMA Dermatology</i> , 2019, 155, 629.	4.1	1
26	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020, 38, 10031-10031.	1.6	1
27	Elderly patientâ€™s tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21536-e21536.	1.6	0
28	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21021-e21021.	1.6	0